Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteNo recent work listed

Kazuma Daiku

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5079652008. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2021: 2 papers · 2022: 4 papers · 2023: 1 paper

Papers 7

  1. Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity. Co-author DOI 10.1186/s13046-023-02831-w↗
  2. Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. Co-author DOI 10.1016/j.jgo.2022.07.010↗
  3. Refractory Lower Limb Edema Resolved by Endovascular Stent Placement for Inferior Vena Cava Stenosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002152↗
  4. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic ca… Co-author DOI 10.1371/journal.pone.0264653↗
  5. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine an… Co-author DOI 10.3390/curroncol29040216↗
  6. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastat… Co-author DOI 10.1002/jgh3.12555↗
  7. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/cancers13184733↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenji Ikezawa · 6 shared papers, 2021–2022 · strength 0.79
  2. Takuo Yamai · 6 shared papers, 2021–2022 · strength 0.79
  3. Ryoji Takada · 6 shared papers, 2021–2022 · strength 0.79
  4. Yugo Kai · 6 shared papers, 2021–2022 · strength 0.79
  5. Kazuyoshi Ohkawa · 6 shared papers, 2021–2022 · strength 0.79
  6. Makiko Urabe · 4 shared papers, 2021–2022 · strength 0.52
  7. Nobuyasu Fukutake · 3 shared papers, 2021–2022 · strength 0.34
  8. Yasuharu Kawamoto · 2 shared papers, 2022 · strength 0.26
  9. Reiko Ashida · 2 shared papers, 2021 · strength 0.22
  10. Masaya Higashiguchi · 1 shared paper, 2023 · strength 0.14
  11. Junya Okabe · 1 shared paper, 2023 · strength 0.14
  12. Katsuhiko Sato · 1 shared paper, 2023 · strength 0.14
  13. Hidetoshi Eguchi · 1 shared paper, 2023 · strength 0.14
  14. Teppei Yoshioka · 1 shared paper, 2023 · strength 0.14
  15. Tetsuo Takehara · 1 shared paper, 2023 · strength 0.14
  16. Teruki Teshima · 1 shared paper, 2021 · strength 0.11
  17. Hirofumi Akita · 1 shared paper, 2021 · strength 0.11
  18. Hidenori Takahashi · 1 shared paper, 2021 · strength 0.11
  19. Kazuhiro Katayama · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.